Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Schochter F, Friedl T, deGregorio A, Krause S, Huober J, Rack B, Janni W. Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Cells 2019; 8
Nov 8, 2019Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Nov 8, 2019Cells 2019; 8
Schochter Fabienne, Friedl Thomas W P, deGregorio Amelie, Krause Sabrina, Huober Jens, Rack Brigitte, Janni Wolfgang
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Heinhuis K, Schilder R, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Britschgi C, Paz-Ares L, Carlino M, Jörger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J, Siu L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2019:1-8.
Nov 7, 2019Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Nov 7, 2019JAMA Oncol 2019:1-8
Heinhuis Kimberley M, Schilder Russell J, O'Byrne Kenneth, Curigliano Giuseppe, Romano Emanuela, Patah Poliana, Wang Rui, Liu Yali, Bajaj Gaurav, Britschgi Christian, Paz-Ares Luis, Carlino Matteo, Jörger Markus, Di Nicola Massimo, Meniawy Tarek, Rottey Sylvie, Moreno Victor, Gazzah Anas, Delord Jean-Pierre, Siu Lillian L
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Müller C, Müller A, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Witjes J, Kamat A, Horwich A, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H, Reijke T, Santis M, Gillessen Sommer S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, Kwast T, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, Bari B, Blok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Jones R. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol 2019; 30:1697-1727.
Nov 1, 2019EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
Nov 1, 2019Ann Oncol 2019; 30:1697-1727
Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J R, Oldenburg J, Osanto S, Oyen W J G, Pacheco-Figueiredo L, Pappot H, Patel M I, Pieters B R, Plass K, Remzi M, Müller C R, Müller A-C, Kiltie A E, Krege S, Ladoire S, Lara P C, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir M Carmen, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Lauridsen S Vahr, Valdagni R, Van Der Heijden A G, Van Poppel H, Vartolomei M D, Veskimäe E, Vilaseca A, Rivera F A Vives, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G N, Rink M, Roghmann F, Rosenberg J E, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R J, Smits A, Stenzl A, Witjes J A, Kamat A M, Horwich A, Arends T, Bamias A, Birtle A, Black P C, Bochner B H, Bolla M, Boormans J L, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H M, Reijke T M De, Santis M De, Gillessen Sommer Silke, James N, Maclennan S, Palou J, Powles T, Ribal M J, Shariat S F, Kwast T Van Der, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D E, Hartmann A, Hayne D, Henry A M, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B A, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, Bari B De, Blok W De, De Visschere P J L, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J L, Fanti S, Fonteyne V, Frydenberg M, Futterer J J, Jones R
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D, ĀăąĆĉČĎ Ā. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915-1928.
Nov 1, 2019Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Nov 1, 2019Lancet 2019; 394:1915-1928
Burtness Barbara, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Hong Ruey-Long, González Mendoza René, Roy Ananya, Zhang Yayan, Gumuscu Burak, Cheng Jonathan D, Jin Fan, Rischin Danny, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers)
Broglie M, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Putora P, Siano M, Henke G, Dulguerov P, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers). Front Oncol 2019; 9:1128.
Oct 24, 2019A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers)
Oct 24, 2019Front Oncol 2019; 9:1128
Broglie Martina A, Negri Sandro V, Rothschild Sacha, Giger Roland, Beffa Lorenza, Ballerini Giorgio, Huber Gerhard, Zwahlen Daniel, Simon Christian, Putora Paul Martin, Siano Marco, Henke Guido, Dulguerov Pavel, Elicin Olgun
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology)
Siano M, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Putora P, Henke G, Broglie M, Dulguerov P, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology). Front Oncol 2019; 9:1127.
Oct 24, 2019A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology)
Oct 24, 2019Front Oncol 2019; 9:1127
Siano Marco, Negri Sandro V, Rothschild Sacha, Giger Roland, Beffa Lorenza, Ballerini Giorgio, Huber Gerhard, Zwahlen Daniel, Simon Christian, Putora Paul Martin, Henke Guido, Broglie Martina A, Dulguerov Pavel, Elicin Olgun
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology)
Elicin O, Dulguerov P, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Broglie M, Siano M, Putora P, Henke G. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology). Front Oncol 2019; 9:1126.
Oct 24, 2019A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology)
Oct 24, 2019Front Oncol 2019; 9:1126
Elicin Olgun, Dulguerov Pavel, Negri Sandro V, Rothschild Sacha, Giger Roland, Beffa Lorenza, Ballerini Giorgio, Huber Gerhard, Zwahlen Daniel, Simon Christian, Broglie Martina A, Siano Marco, Putora Paul Martin, Henke Guido
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery)
den Hollander J, Negri S, Rothschild S, Giger R, Beffa L, Ballerini G, Huber G, Zwahlen D, Simon C, Putora P, Siano M, Henke G, Broglie M, Elicin O. A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery). Front Oncol 2019; 9:1125.
Oct 24, 2019A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery)
Oct 24, 2019Front Oncol 2019; 9:1125
den Hollander Jürgen, Negri Sandro V, Rothschild Sacha, Giger Roland, Beffa Lorenza, Ballerini Giorgio, Huber Gerhard, Zwahlen Daniel, Simon Christian, Putora Paul Martin, Siano Marco, Henke Guido, Broglie Martina A, Elicin Olgun
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Crombag M, Koolen S, Wijngaard S, Jörger M, Dorlo T, van Erp N, Mathijssen R, Beijnen J, Huitema A. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. Pharm Res 2019; 36:163.
Oct 15, 2019Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?
Oct 15, 2019Pharm Res 2019; 36:163
Crombag Marie-Rose B S, Koolen Stijn L W, Wijngaard Sophie, Jörger Markus, Dorlo Thomas P C, van Erp Nielka P, Mathijssen Ron H J, Beijnen Jos H, Huitema Alwin D R
Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB
De Gregorio A, Widschwendter P, Ebner F, Friedl T, Huober J, Janni W, De Gregorio N. Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB. Oncology 2019; 98:91-97.
Oct 8, 2019Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB
Oct 8, 2019Oncology 2019; 98:91-97
De Gregorio Amelie, Widschwendter Peter, Ebner Florian, Friedl Thomas Wolfram Paul, Huober Jens, Janni Wolfgang, De Gregorio Nikolaus
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
Golshan M, Sikov W, Geyer C, von Minckwitz G, Metzger-Filho O, Sullivan D, Maag D, Ansell P, Wolmark N, Rugo H, O'Shaughnessy J, Huober J, Loibl S, Wong S, Untch M. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol 2019; 46:223-228.
Oct 5, 2019Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
Oct 5, 2019Eur J Surg Oncol 2019; 46:223-228
Golshan Mehra, Sikov William M, Geyer Charles E, von Minckwitz Gunter, Metzger-Filho Otto, Sullivan Danielle M, Maag David, Ansell Peter, Wolmark Norman, Rugo Hope S, O'Shaughnessy Joyce, Huober Jens, Loibl Sibylle, Wong Stephanie M, Untch Michael
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Mottet N, Sedelaar J, Schoots I, Richenberg J, Sancho Pardo G, Rouvière O, Rouprêt M, Roobol M, Ribal M, Renard-Penna R, Paterson C, Pang K, Omar M, Moris L, Lin D, Liew M, Stricker P, Tilki D, Cornford P, Van Poppel H, N'Dow J, Zattoni F, Wilkinson K, Wiegel T, Wallis C, Violette P, Varma M, van Leenders G, van der Poel H, van der Kwast T, Van den Broeck T, van den Bergh R, Vahr Lauridsen S, Lardas M, Irani J, Ingels A, Cox B, Colecchia M, Catto J, Buddingh K, Briganti A, Briers E, Bossi A, Bjartell A, Bangma C, Baanders R, Shepherd R, Plass K, Mason M, Willemse P, MacLennan S, Cumberbatch M, Davies J, Henry A, Grummet J, Gross T, Grivas N, Gillessen Sommer S, Gandaglia G, Fossati N, Fanti S, Fankhauser C, Egawa S, Donaldson J, Deschamps A, Dell'Oglio P, De Santis M, Davis N, Lam T. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol 2019; 76:790-813.
Oct 3, 2019EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Oct 3, 2019Eur Urol 2019; 76:790-813
Mottet Nicolas, Sedelaar J P Michiel, Schoots Ivo G, Richenberg Jonathan, Sancho Pardo Gemma, Rouvière Olivier, Rouprêt Morgan, Roobol Monique J, Ribal Maria J, Renard-Penna Raphaële, Paterson Catherine C, Pang Karl H, Omar Muhammad Imran, Moris Lisa, Lin Daniel W, Liew Matthew, Stricker Phillip, Tilki Derya, Cornford Philip, Van Poppel Hendrik, N'Dow James M O, Zattoni Fabio, Wilkinson Karen, Wiegel Thomas, Wallis Christopher J D, Violette Philippe D, Varma Murali, van Leenders Geert J L H, van der Poel Henk G, van der Kwast Theodorus H, Van den Broeck Thomas, van den Bergh Roderick C N, Vahr Lauridsen Susanne, Lardas Michael, Irani Jacques, Ingels Alexandre, Cox Brett W, Colecchia Maurizio, Catto James W F, Buddingh Karel T, Briganti Alberto, Briers Erik, Bossi Alberto, Bjartell Anders, Bangma Chris H, Baanders Ruud, Shepherd Robert, Plass Karin, Mason Malcolm D, Willemse Peter-Paul M, MacLennan Steven, Cumberbatch Marcus G, Davies Jeff, Henry Ann M, Grummet Jeremy P, Gross Tobias, Grivas Nikolaos, Gillessen Sommer Silke, Gandaglia Giorgio, Fossati Nicola, Fanti Stefano, Fankhauser Christian D, Egawa Shin, Donaldson James F, Deschamps André, Dell'Oglio Paolo, De Santis Maria, Davis Niall F, Lam Thomas B L
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
Oct 1, 2019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Oct 1, 2019Ann Oncol 2019; 30:1541-1557
Burstein H J, Thürlimann Beat, Winer E P, Senn H-J, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019
Sep 27, 2019Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Sep 27, 2019Ann Oncol 2019
James N D, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Srihari N N, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Varga Z, Thürlimann B, Klingbiel D, Hawle H, Tille J, Rau T, Perriard U, Jochum W, Li Q, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.
Sep 19, 2019Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Sep 19, 2019Sci Rep 2019; 9:13534
Varga Zsuzsanna, Thürlimann Beat, Klingbiel Dirk, Hawle Hanne, Tille Jean-Christoph, Rau Tilman, Perriard Ulrike, Jochum Wolfram, Li Qiyu, Ruhstaller Thomas
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
Luftner D, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Kolberg H, Jackisch C, Bauerfeind I, Braun M, Brucker S, Fasching P, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 2019; 14:315-324.
Sep 17, 2019Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
Sep 17, 2019Breast Care (Basel) 2019; 14:315-324
Luftner Diana, Kolberg-Liedtke Cornelia, Kühn Thorsten, Maass Nicolai, Reimer Toralf, Schneeweiss Andreas, Schumacher-Wulf Eva, Schütz Florian, Thomssen Christoph, Untch Michael, Wuerstlein Rachel, Kolberg Hans-Christian, Jackisch Christian, Bauerfeind Ingo, Braun Michael, Brucker Sara Y, Fasching Peter A, Felberbaum Ricardo, Hagemann Friederike, Haidinger Renate, Harbeck Nadia, Hönig Arnd, Huober Jens, Thill Marc
Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015
Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, Feller A, NICER Working Group. Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. Cancer Epidemiol 2019; 63:101596.
Sep 11, 2019Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015
Sep 11, 2019Cancer Epidemiol 2019; 63:101596
Kollár Attila, Rothermundt Christian, Klenke Frank, Bode Beata, Baumhoer Daniel, Arndt Volker, Feller Anita, NICER Working Group
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
Sep 10, 2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sep 10, 2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
VanderWeele D, Sweeney C, Petrylak D, Morgans A, Higano C, Gillessen Sommer S, Fizazi K, Dreicer R, Carducci M, Antonarakis E, Hussain M. Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. J Clin Oncol 2019; 37:2961-2967.
Sep 10, 2019Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
Sep 10, 2019J Clin Oncol 2019; 37:2961-2967
VanderWeele David J, Sweeney Christopher J, Petrylak Daniel P, Morgans Alicia K, Higano Celeste S, Gillessen Sommer Silke, Fizazi Karim, Dreicer Robert, Carducci Michael A, Antonarakis Emmanuel S, Hussain Maha
[Molecularly-targeted anticancer treatments - a short appraisal]
Jörger M. [Molecularly-targeted anticancer treatments - a short appraisal]. Ther Umsch 2019; 76:179-185.
Sep 1, 2019[Molecularly-targeted anticancer treatments - a short appraisal]
Sep 1, 2019Ther Umsch 2019; 76:179-185
Jörger Markus